| Revision as of 08:54, 1 September 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'DrugBank_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'DrugBank_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report errors o← Previous edit |
Latest revision as of 11:44, 15 January 2024 edit undoMaxim Masiutin (talk | contribs)Extended confirmed users, IP block exemptions, Pending changes reviewers31,043 edits Added s2cid. Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors. |
| (13 intermediate revisions by 12 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
|
{{cs1 config|name-list-style=vanc}} |
|
{{Drugbox |
|
{{Drugbox |
|
|
| Watchedfields = changed |
|
| verifiedrevid = 443996506 |
|
| verifiedrevid = 447824918 |
|
| IUPAC_name = (1''R'',5''R'')-3-(dicyclohexylmethoxy)-8-ethyl-<br>8-azabicyclooctane |
|
| IUPAC_name = (3-''endo'')-3-(Diphenylmethoxy)-8-ethyl-8-azabicyclooctane |
|
| image = Etybenzatropine.svg |
|
| image = Etybenzatropine.svg |
|
|
|
|
| Line 9: |
Line 12: |
|
|
|
|
|
<!--Identifiers--> |
|
<!--Identifiers--> |
|
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number = 524-83-4 |
|
| CAS_number = 524-83-4 |
|
| ATC_prefix = N04 |
|
| ATC_prefix = N04 |
| Line 22: |
Line 26: |
|
<!--Chemical data--> |
|
<!--Chemical data--> |
|
| C=22 | H=27 | N=1 | O=1 |
|
| C=22 | H=27 | N=1 | O=1 |
|
⚫ |
| smiles = CCN12CC1C(C2)OC(c3ccccc3)c4ccccc4 |
|
| molecular_weight = 321.456 g/mol |
|
| ⚫ |
| smiles = CCN41CC4C(C1)OC(c2ccccc2)c3ccccc3 |
|
|
| InChI = 1/C22H27NO/c1-2-23-19-13-14-20(23)16-21(15-19)24-22(17-9-5-3-6-10-17)18-11-7-4-8-12-18/h3-12,19-22H,2,13-16H2,1H3/t19-,20+,21+ |
|
|
| InChIKey = PHTMLLGDZBZXMW-AERCQKQUBH |
|
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI = 1S/C22H27NO/c1-2-23-19-13-14-20(23)16-21(15-19)24-22(17-9-5-3-6-10-17)18-11-7-4-8-12-18/h3-12,19-22H,2,13-16H2,1H3/t19-,20+,21+ |
|
| StdInChI = 1S/C22H27NO/c1-2-23-19-13-14-20(23)16-21(15-19)24-22(17-9-5-3-6-10-17)18-11-7-4-8-12-18/h3-12,19-22H,2,13-16H2,1H3/t19-,20+,21+ |
| Line 32: |
Line 33: |
|
}} |
|
}} |
|
|
|
|
|
'''Etybenzatropine''' (]), also known as '''ethybenztropine''' (], ]) and '''tropethydrylin''', is an ]/] marketed under the ]s '''Panolid''', '''Ponalid''', and '''Ponalide''', which is used as an ]. Like its ] ], it may act as a ].{{Citation needed|date=June 2011}} |
|
'''Etybenzatropine''' (]), also known as '''ethybenztropine''' (], ]) and '''tropethydrylin''', is an ]/] marketed under the ]s '''Panolid''', '''Ponalid''', and '''Ponalide''', which is used as an ].<ref name="pmid2779590">{{cite journal | vauthors = Pourcher E, Bonnet AM, Kefalos J, Dubois B, Agid Y | title = Effects of etybenzatropine and diazepam on levodopa-induced diphasic dyskinesias in Parkinson's disease | journal = Movement Disorders | volume = 4 | issue = 3 | pages = 195–201 | date = 1989 | pmid = 2779590 | doi = 10.1002/mds.870040301 | s2cid = 1826853 }}</ref> Like its ] ], it may act as a ].{{Citation needed|date=June 2011}} |
|
|
|
|
|
== See also == |
|
== See also == |
| Line 39: |
Line 40: |
|
== References == |
|
== References == |
|
{{Reflist|2}} |
|
{{Reflist|2}} |
|
|
|
|
|
|
|
|
{{Antiparkinson}} |
|
{{Antiparkinson}} |
|
|
{{Navboxes |
|
{{Cholinergics}} |
|
|
|
| title = ] |
|
{{Dopaminergics}} |
|
|
|
| titlestyle = background:#ccccff |
|
{{Histaminergics}} |
|
|
|
| list1 = |
|
|
{{Histamine receptor modulators}} |
|
|
{{Monoamine reuptake inhibitors}} |
|
|
{{Muscarinic acetylcholine receptor modulators}} |
|
|
}} |
|
|
|
|
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
|
|
|
|
|
|
|
|
{{nervous-system-drug-stub}} |
|
{{nervous-system-drug-stub}} |
|
|
|
|
] |
|